Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Weekly Report Card
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(26)
•••
Comment by Bucknelly21on Jul 11, 2021 2:04pm
114 Views
Post# 33527897

RE:RE:RE:RE:RE:RE:RE:Weekly Report Card

RE:RE:RE:RE:RE:RE:RE:Weekly Report Card
jfm1330 wrote: First I am not in a position to fight anything. I am just tired of seeing this board taken over by this subject. I explained my view here many times. I think most of this situation is out of the management's hands. No promotion or propaganda will change the actual perception of the company. Only very clear positive and meaningful hard facts would change that quickly, and the phase I in oncology is the only hope that it could happen and there are many reasons to think that it could happen, but until it happens, nothing is sure. We have to wait and look out for any positive signs we can detect ahead of the real results. But as I said here many times, the more the time is going by without a news, the better it is.


SPCEO1 wrote: And I am prettysure you would not mind all that much if those gaps were closed, so why fight it?   


the same clear hard facts like cydy has?

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities